ESMO 2020 Conference Highlights eBOOK
ESMO 2020 Lung Cancer Conference Report In Focus: Lung Cancer Durvalumab Demonstrates...
ESMO
Amivantamab-Lazertinib Combo for Resistant EGFR-positive NSCLC
At the European Society for Medical Oncology (ESMO) Virtual Congress 2020 , lead study investigator Prof. Byoung Chul Cho (Yonsei Cancer Centre, Yonsei University College of Medicine in Seoul, South Korea) presented the interim...
4-Year PACIFIC Data Hold Strong for Durvalumab in NSCLC
At the ESMO Virtual Congress 2020 held 19-21 September, 2020, updated post-hoc findings from the...
Phase III ADAURA Trial: CNS Recurrences slashed for NSCLC
Physician’s Weekly interviews principle investigator, Roy S. Herbst, MD, PhD, Ensign...
ESMO: Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC
Lorlatinib is a third generation ALK tyrosine kinase inhibitor. The phase 3 CROWN study shows...
ESMO: Bispecific antibodies targeting PD-1 and CTLA-4: new kids on the block(ade)
Several clinical trials have showed that combining an anti-CTLA-4 inhibitor and an anti-PD-(L)1...
ESMO: PD-L1 density, a new predictive biomarker in NSCLC
PD-L1 expression is commonly used to predict response to immune checkpoint inhibitor therapy....
ESMO: Adjuvant osimertinib in NSCLC reduces risk of CNS recurrence
Patients with resectable non-small cell lung cancer (NSCLC) often develop (fatal) distant...
ESMO: No advantage of post-operative radiotherapy in patients with stage IIIA N2 NSCLC
The merits of post-operative radiotherapy (PORT) in completely resected non-small cell lung cancer...
ESMO: Is adding an immune checkpoint inhibitor to targeted therapy the right approach?
According the primary results of the COMBI-i trial, the addition of PD1 inhibitor spartalizumab to...
ESMO: Is KRAS Finally ’Druggable’?
Sotorasib results promising in phase 1 trial Results of a 129-patient phase I trial of sotorasib,...
ESMO: Adjuvant Osimertinib Achieves Significant Benefit in EGFR Positive NSCLC
Efficacy observed for stage IB-IIIA disease Patients with resectable stage IB to III...
